Cabozantinib (Cometriq®) is a type of medication called a Tyrosine Kinase Inhibitor. It works by blocking two molecules, called c-MET and VEGFR, which are required by cancer cells to grow and divide. It is approved for the treatment of kidney cancer and liver cancer in many jurisdictions.
The other drugs in this study are called Ipilimumab (Yervoy®) and Nivolumab (Opdivo®). These are immunotherapy drugs that are already approved for the treatment of kidney cancer in Canada.
The purpose of this trial is to determine whether the addition of Cabozantinib to the standard combination of Ipilimumab and Nivolumab can improve treatment efficacy among patients with advanced kidney cancer.
Patients enrolling on this study will be randomly assigned to one of two groups:
- Cabozantinib + Ipilimumab/Nivolumab (The Experimental Group)
- Placebo + Ipilimumab/Nivolumab (The Control Group)
Many clinical trials include a control group so that researchers can tell whether the effect is due to the treatment, or just reflects the natural behaviour of the tumour. A placebo will be administered to the control group so that neither you nor the researchers will know which group you are in.
- Clear cell kidney cancer
- Cancer has spread or cannot be removed by surgery
- Received no prior drug treatment
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreExelixis Clinical Site #22||Principal Investigator||LocationCalgary, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreExelixis Clinical Site - Winnipeg||Principal Investigator||LocationWinnipeg, MB||Trial StatusRecruiting|
|Hospital / Cancer CentreExelixis Clinical Site #46||Principal Investigator||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreExelixis Clinical Site #25||Principal Investigator||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreExelixis Clinical Site - Montréal||Principal Investigator||LocationMontreal, QC||Trial StatusRecruiting|